- Home
- CHPT vs ENLV Comparison
CHPT vs ENLV Comparison
Compare CHPT & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CHPT | ENLV |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.0M | 149.0M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CHPT | ENLV |
|---|---|---|
| Price | $10.35 | $0.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 9 | 2 |
| Target Price | $9.25 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 3.4M | 281.6K |
| Earning Date | 06-03-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $411,224,000.00 | N/A |
| Revenue This Year | $4.18 | N/A |
| Revenue Next Year | $16.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.44 | $0.43 |
| 52 Week High | $12.61 | $7.64 |
Technical Indicators
Market Signals| Indicator | CHPT | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 74.01 | 27.10 |
| Support Level | $5.39 | $0.72 |
| Resistance Level | $10.43 | $0.94 |
| Average True Range (ATR) | 0.77 | 0.13 |
| MACD | 0.22 | 0.00 |
| Stochastic Oscillator | 93.15 | 19.59 |
Price Performance
Historical ComparisonAbout CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable charging systems owners, charge point operators, to manage their Networked Charging Systems, and to enable drivers to locate, reserve and authenticate Networked Charging Systems and to transact EV charging sessions on those systems. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. The company derives the majority of its revenue from the United States.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.